Abstract:Antibodies currently constitute the most rapidly growing class of human therapeutics; however, the high-yield production of recombinant antibodies and antibody fragments is a real challenge. High expression of active single-chain antibody fragment (scFv) in Escherichia coli has not been successful, as the protein contains three intramolecular disulfide bonds that are difficult to form correctly in the bacterial intracellular environment. To solve this problem, we fused the scFv gene against VEGF165 with a small ubiquitin-related modifier gene (SUMO) by synthesizing an artificial SUMO–scFv fusion gene that was highly expressed in the BL21(DE3) strain. The optimal expression level of the soluble fusion protein, SUMO–scFv, was up to 28.5% of the total cellular protein. The fusion protein was purified by Ni nitrilotriacetic acid (NTA) affinity chromatography and cleaved by a SUMO-specific protease to obtain the native scFv, which was further purified by Ni-NTA affinity chromatography. The result of the high-performance liquid chromatography showed that the purity of the recombinant cleaved scFv was greater than 98%. The primary structure of the purified scFv was confirmed by N-terminal amino acid sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy analysis. In vitro activity assay demonstrated that the recombinant scFv could dose-dependently inhibit VEGF165-induced human umbilical vein-derived endothelial cell proliferation. The expression strategy presented in this study allows convenient high yield and easy purification of recombinant scFv with native sequences.

The Screening,Expression and Purification of Single Chain Fv(scFv) Against Vascular Endothelial Growth Factor Receptor 2

Research on Inhibition Activity of a Single Chain Fv (scFv) against Vascular Endothelial Growth Factor Receptor 2

Bioscreening of Phage Display Antibody Library and Expression of A Humanized Single-Chain Variable Fragment Antibody Against Human Connective Tissue Growth Factor (Ctgf/ccn2)

Screening,expression and activity identification of anti-CTGF human single-chain Fv

Screening and Identification of Scfv Against Hepatoma Carcinoma Cell

Screening of Humanized Single-Chain Variable Fragments Against Connective Tissue Growth Factor

Screening, Expression and Characterization of Single Chain Fv (scfv) Against Basic Fibroblast Growth Factor

Generation of single-chain antibody against angiopoietin 2 by phage display peptide technique

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Construction,Expression and Biological Activity Studies of a Bivalent Single Chain Variable Fragment (BsFv)against Vascular Endothelial Growth Factor Receptor 2

High-level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in Escherichia coli

Soluble Expression and Purification of a Novel Single-Chain Fv Antibody Against Connective Tissue Growth Factor(ctgf/ccn2)

[Expression, Purification and Activity Analysis of Human Single-Chain Antibody Against Hepatocellular Cancer].

[Selection and Characterization of Human Antibodies Against Vascular Endothelial Growth Factor from Human Phage Display Antibody Library].

Prokaryotic Expression of VEGF165 and Preliminary Screening of Anti-VEGF Hybridoma Cell Lines

Screening and characterization of human anti-GPC3 single chain Fv antibody fragment selected by phage display

Identification of a Neutralizing scFv Binding to Human Vascular Endothelial Growth Factor 165 (VEGF165) Using a Phage Display Antibody Library

Construction and Screening of Phage Antibody Libraries Against Epidermal Growth Factor Receptor Variant Type Ⅲ

Screening of Scfvs Against Ctni from Phage Display Antibody Library and Their Expression in E. Coli Rosetta

Screening of scFvs against cTnI from Phage Display Antibody Library and Their Expression in E.coli Rosetta

Generation and Characterization of a Novel Human IgG1 Antibody Against Vascular Endothelial Growth Factor Receptor 2